Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Mediterranean Journal of Hematology and Infectious Diseases|February 21, 2012
Primary pancreatic lymphoma in a patient with maturity onset diabetes of the young type 3Valentina Bozzoli, Maria Chiara Tisi, Luigi Pianese, et al.
Leukemia & Lymphoma|October 13, 2015
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphomaMaria Chiara Tisi, Elisa Cupelli, Rosaria Santangelo, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cellsAnna Dalla Pietà, Elisa Cappuzzello, Pierangela Palmerini, et al.
Leukemia & Lymphoma|May 8, 2013
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietinMaria Chiara Tisi, Valentina Bozzoli, Manuela Giachelia, et al.
Cancers|December 10, 2021
Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell LymphomaGiulia Bega, Jacopo Olivieri, Marcello Riva, et al.
Leukemia & Lymphoma|April 29, 2020
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphomaMichele Merli, Irene Defrancesco, Carlo Visco, et al.
Frontiers in Oncology|December 23, 2021
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana LinfomiLaura Ballotta, Pier Luigi Zinzani, Stefano Pileri, et al.
British Journal of Haematology|October 15, 2020
Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective studyGessica Marchesini, Gianpaolo Nadali, Davide Facchinelli, et al.
Hematological Oncology|May 25, 2022
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study)Luigi Rigacci, Roberta Battistini, Sofia Kovalchuk, et al.
British Journal of Haematology|June 15, 2024
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE studyAngelica Barone, Annalisa Chiappella, Beatrice Casadei, et al.
Pageof 6